Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

Wei Wei, Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang, Xin Huang, Yongwen Huang, Qiaqia Li, Ya Qiu, Min Zheng, Xiao‐Feng Zhu, Jundong LiJournal for ImmunoTherapy of Cancer 2022 · DOI

Abstract

Background: Patients with recurrent or advanced endometrial cancer (EC) who progress after platinum-based chemotherapy have limited treatment options and poor prognosis. This Phase II trial (NCT04157491) investigated the efficacy, safety, and potential biomarkers of the combination of sintilimab (anti-PD-1) and anlotinib (multi-targeted TKI). Methods: 23 patients were enrolled and treated with sintilimab and anlotinib. The primary endpoint was objective response rate (ORR). Genomic analysis was performed to identify biomarkers. Results: The ORR was 73.9%, with a disease control rate of 91.3%. Efficacy was observed in both MSI-H/dMMR (100% ORR) and MSS/pMMR (57.1% ORR) subgroups. Mutations in the Homologous Repair (HR) pathway and LYN gene were identified as potential biomarkers for response and resistance, respectively. Conclusion: Sintilimab plus anlotinib demonstrates robust antitumor activity and manageable toxicity in advanced EC, representing a promising "chemo-free" second-line strategy.

Introduction

Endometrial cancer (EC) is a significant health burden with rising incidence and mortality. For patients failing first-line platinum-based therapy, second-line options are limited. Immunotherapy has shown efficacy primarily in the ~30% of patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status. The majority of patients have microsatellite stable (MSS) or proficient mismatch repair (pMMR) tumors, which are often resistant to PD-1/PD-L1 inhibitors. Combining immunotherapy with anti-angiogenic agents like anlotinib may overcome this resistance by modulating the tumor microenvironment. This study evaluates the sintilimab plus anlotinib combination in a Chinese patient population.

Methods

This was a single-arm, open-label Phase II trial. Eligible patients had recurrent or advanced EC and had progressed after at least one line of platinum-based chemotherapy. Patients received sintilimab (200 mg IV every 3 weeks) and anlotinib (12 mg orally, 2 weeks on/1 week off). Response was assessed using irRECIST criteria. Exploratory biomarker analyses included Whole Exome Sequencing (WES) and a 425-gene targeted panel on tumor tissue and blood.

Results

A total of 23 patients were evaluable for efficacy. The objective response rate (ORR) was 73.9% (17/23), including 4 complete responses (CR) and 13 partial responses (PR). The disease control rate (DCR) reached 91.3%.

Antitumor activity of sintilimab plus anlotinib. (A) Waterfall plot of best percentage change from baseline in target lesions. (B) Spider plot showing longitudinal change in tumor burden. (C) Swimmer plot of treatment duration and response status.

The median time to response was 2.8 months. At a median follow-up of 15.4 months, the median progression-free survival (PFS) had not been reached. Subgroup analysis showed a 100% ORR in MSI-H/dMMR patients and a 57.1% ORR in MSS/pMMR patients, highlighting the regimen's efficacy in typically immunotherapy-resistant tumors.

Biomarker analysis identified mutations in the Homologous Repair (HR) pathway (e.g., BRCA2, ATM) as a potential positive predictor, with a 100% response rate in mutated patients. Conversely, LYN mutations were associated with significantly shorter PFS, indicating a potential mechanism for treatment resistance.

Safety

The safety profile was manageable. Grade 3/4 adverse events occurred in 50% of patients. Notably, Grade 3 hypertension occurred in only 4.3% of patients, suggesting better tolerability compared to other anti-angiogenic combinations used in this setting.

Discussion

The combination of sintilimab and anlotinib provides a highly effective and durable treatment option for patients with advanced EC, regardless of microsatellite status. The high ORR in the MSS/pMMR subgroup is particularly encouraging. The identification of HR pathway and LYN mutations as biomarkers offers a path toward personalized treatment strategies. While limited by a small sample size, these results support further investigation in larger, randomized trials.

Summary updated

Abstract

NCT04157491.
BibTeX
@article{wei2022phase,
  author = {Wei Wei and Xiaohua Ban and Fan Yang and Jibin Li and Xiaqin Cheng and Rong Zhang and Xin Huang and Yongwen Huang and Qiaqia Li and Ya Qiu and Min Zheng and Xiao‐Feng Zhu and Jundong Li and Jundong Li and Jundong Li},
  title = {{Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer}},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2022},
  doi = {10.1136/jitc-2021-004338},
}
Figure